Research programme: influenza A virus H1N1 vaccine - TakedaAlternative Names: Vaccines against new forms of influenza - Takeda
Latest Information Update: 23 Jul 2014
At a glance
- Originator Inviragen
- Developer Takeda Pharmaceuticals USA
- Class Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H1N1 subtype